Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Completed

• Conditions: Polypoidal Choroidal Vasculopathy

• Registration Number: NCT01271426
• Lead Sponsor: Nihon University

Brief Summary

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-04
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Status Verified: 2011-01
• Study First Submitted: 2011-01-05
• Study First Submitted QC: 2011-01-05
• Last Update Submitted: 2011-01-05
• Study First Posted: 2011-01-06
• Last Update Posted: 2011-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• Clinical diagnosis of Polypoidal choroidal vasculopathy
• must have injection of Ranibizumab

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab	a month after injection

Trial Locations

Locations (1)

Surugadai Nihon university hospital; 🇯🇵 1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan